

32692

Customer Number

Patent  
Case No.: 59091US005

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Named Inventor: WIGHTMAN, PAUL D.

Application No.: 10/595066

Confirmation No.: 2105

Filed: August 12, 2004

Title: LIPID-MODIFIED IMMUNE RESPONSE MODIFIERS

**RESPONSE TO RESTRICTION REQUIREMENT—ELECTION OF SPECIES**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR § 1.8(a)]**

I hereby certify that this correspondence is being:

☐ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 571-273-8300.

☒ transmitted to United States Patent and Trademark Office on the date shown below via the Office electronic filing system.

6/12/2008  
Date

Megan L. Rindlisbacher  
Signed by: Megan L. Rindlisbacher


Dear Sir:

In response to the Examiner's office action dated 05/14/2008, Applicants provisionally elect the species described in claim 29, namely *N*-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)hexadecanamide, the structure of which is shown in Example 1.

The claims which read on the elected species are: 1, 7, 11, 13, 14, 17, 18, 20, 21, 24, 25, 28, 29, 33, 34, and 35. Claims 1, 7, 11, 13, 14, 17, 18, 20, 21, 24, 25, 28, 33, 34, and 35 are generic to the elected species.

This election is with traverse to the extent that it is understood that (a) the requirement will be withdrawn upon the finding of an allowable genus; and (b) any species withdrawn from consideration will be transferred to the elected subject matter unless it is found patentably distinct from the elected or allowed claims. Applicants traverse on the grounds that the generic claim includes sufficiently few species that a search and examination of all the species at one time would not impose a serious burden on the Examiner. It is believed that a search of the classes appropriate to the elected species and claim 29 would include the Patent Office classes in which the non-elected

species and claims 1, 7, 11, 13, 14, 17, 18, 20, 21, 24, 25, 28, 33, 34, and 35 would be searched, as each claim requires a compound which includes the structure:



, R<sub>1</sub> being within the meaning of alkylene-L-R<sub>1-1</sub>, alkenylene-L-R<sub>1-1</sub>, or alkynylene-L-R<sub>1-1</sub> (\* being the groups defined at these positions in each claim).

### Conclusion

Applicants have elected the single disclosed species, N-(2-{2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy}ethyl)hexadecanamide. Continued prosecution of this application is respectfully requested.

It is believed that no fee is due; however, in the event a fee is required, please charge the fee to Deposit Account No. 13-3723. Should the Examiner determine that a telephone interview would be beneficial in resolving any issue in this case, the Examiner is invited to telephone the undersigned agent at the telephone number noted below.

Respectfully submitted,

11 June 2008  
Date

By: Dean A. Ersfeld  
Dr. Dean A. Ersfeld, Reg. No.: 46,689  
Telephone No.: 651-733-7830

Office of Intellectual Property Counsel  
3M Innovative Properties Company  
Facsimile No.: 651-736-3833